iProtics is a Leiden biotech company advancing IP071, a peptide inhibitor that selectively targets immunoproteasomes in malignant cells, offering 12‑fold higher selectivity than existing drugs like Carfilzomib. Building on Leiden University research and backed by UNIIQ and Biotech Booster, it develops safer, more effective therapies for cancer and autoimmune disorders.